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Editorial
Revisiting mycophenolate mofetil for
steroid-refractory acute graft-versus-host
disease: Is higher dosing effective in children?
Survival following allogeneic hematopoietic stem
cell transplantation (HSCT) has steadily
improved over time in all age groups, including
children, even with increasing use of non-sibling
donors (1, 2). Much of the improvement in out-
comes is due to more effective strategies that
have reduced the incidence of acute graft-versus-
host disease (GVHD) (3). Nonetheless, acute
GVHD remains the primary cause of non-relapse
mortality (NRM) after allogeneic transplanta-
tion (4). It is steroid-refractory acute GVHD,
primarily involving the lower gastrointestinal
(GI) tract, that accounts for the vast majority of
NRM (5). Unfortunately, there are no proven
treatments for steroid-refractory acute GVHD
despite over 40 yr of clinical trials. It is in this
context that Inagaki et al. (6) studied mycophen-
olate mofetil (MMF) as a treatment for steroid-
refractory acute GVHD as reported in this issue
of Pediatric Transplantation.
Inagaki et al. analyzed the effectiveness of oral
MMF in 14 children with steroid-refractory
acute GVHD that had not responded to at least
two lines of treatment before beginning MMF.
They report an impressive 83% response rate at
eight wk after initiation, which included an
equally high response rate in patients with GI
GVHD. The vast majority of patients remained
alive, in remission, and off all immunosuppres-
sion at a median of almost three yr of follow-up.
Although second-line therapies are often associ-
ated with significant toxicities (7), MMF was
very well tolerated in this study. The authors
attribute the success of their treatment to the
high starting dose (>40 mg/kg/day) and further
dose escalation due to poor initial dose response,
an approach supported by data showing a strong
dose–response relationship between MMF and
acute GVHD incidence and response to treat-
ment (8, 9).
Although the results from this study are prom-
ising, they are far from definitive, especially in
light of the small numbers of patients studied.
Only oral MMF was used despite the high inci-
dence of voluminous diarrhea, and no pharma-
cokinetic studies were performed, so we cannot
be sure whether the high dosing actually led to
higher blood concentrations of active drug. Also,
several patients responded despite cessation of
steroid therapy prior to initiating MMF, a strat-
egy that raises questions as to how steroid-refrac-
tory the GVHD was in some patients. We also
do not know whether some of the responses
observed were from ongoing or delayed response
to second- or higher line therapy already admin-
istered. In addition, we need to reconcile the
results of this study with the large, multicenter,
phase III randomized, controlled trial that failed
to show any benefit from MMF compared to
placebo when used in combination with steroids
to treat newly diagnosed acute GVHD (10).
Although Inagaki et al. observed excellent
responses to MMF in their patients, we do not
know whether these results will be reproducible
in future trials. If we can identify patients whose
GVHD will be resistant to frontline therapy
before treatment failure has occurred, we may be
able to design better clinical trials in the future.
There has been intensive effort recently to
develop staging systems that will help us catego-
rize patients for risk of treatment failure when
they are diagnosed with GVHD. MacMillan
et al. (11) developed a clinical risk score for acute
GVHD that predicts response to treatment,
NRM, and survival based on GVHD target
organ involvement and clinical severity when
treatment is begun. Patients with isolated, but
severe skin, GI, or liver involvement, and most
combinations of multi-organ GVHD, are classi-
fied as high risk and comprise approximately
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15% of all GVHD cases treated. These patients
experience low response rates to initial steroid
therapy (43% complete or partial response rate
by day 28 of treatment), high six-month NRM
(44%), and poor six-month survival (53%).
Plasma concentrations of GVHD biomarkers,
alone or in combination, have also been exten-
sively studied for their ability to predict response
to treatment, NRM, and survival (12–14). The
recently published Ann Arbor GVHD scoring
system defined and validated three risk strata
based entirely on the plasma concentrations of
three GVHD biomarkers, TNFR1, REG3a, and
ST2 measured at GVHD diagnosis in a training
cohort and two independent validation sets (5).
This study included patients whose initial treat-
ment did not include systemic immunosuppres-
sion such as those who presented with limited
GVHD skin rashes. Patients with high-risk (Ann
Arbor 3) GVHD, who comprise 22% of all
GVHD cases, experienced low response rates to
initial therapy (46%), high 12-month NRM
(49%), and low 12-month survival (45%). Either
scoring system, or possibly a combination, repre-
sents a new opportunity to tailor primary ther-
apy according to the risk of steroid-refractory
GVHD before it develops, when it is more likely
to respond.
In summary, Inagaki et al. have revived inter-
est in MMF as a GVHD treatment, at least for
children with steroid-refractory GVHD. New
GVHD scoring systems that can be applied at
diagnosis may lead to better designed clinical tri-
als in the future that focus on improving out-
comes for high-risk patients. For example, it is
possible that agents that previously failed to
show benefit for initial GVHD treatment, such
as MMF, may yet prove efficacious when tested
only in high-risk patients, especially if dosing is
determined based on pharmacokinetics. If this is
indeed the case, it could help reconcile the cur-
rent contradictory results between the present
positive study (6) and the negative randomized
controlled trial (10).
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